Sanofi (NASDAQ:SNY) Shares Purchased by World Investment Advisors LLC

World Investment Advisors LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 1,020.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,430 shares of the company’s stock after buying an additional 44,108 shares during the quarter. World Investment Advisors LLC’s holdings in Sanofi were worth $2,791,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the 2nd quarter worth $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi during the third quarter worth about $29,000. Concord Wealth Partners lifted its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new stake in shares of Sanofi in the second quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC increased its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Down 0.4 %

SNY stock opened at $46.80 on Friday. The company has a 50 day moving average price of $51.02 and a two-hundred day moving average price of $52.04. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a market capitalization of $118.77 billion, a P/E ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the previous year, the business earned $2.55 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.